Summary.
Mycobacterium tuberculosis (Mtb) has evolved to become the single greatest cause of death from an infectious agent. The pathogen spends most of its infection cycle in its human host within a phagocyte. The bacterium has evolved to block the normal maturation and acidification of its phagosome, and resides in a vacuole contiguous with the early endosomal network. Cytokine-mediated activation of the host cell can overcome this blockage and an array of anti-microbial responses can limit its survival.
The survival of Mtb in its host cell is fueled predominantly by fatty acids and cholesterol. Mtb’s ability to degrade sterols is an unusual metabolic characteristic that was likely retained from a saprophytic ancestor. Recent results with fluorescent Mtb reporter strains demonstrate that bacterial survival differs with the host macrophage population. Tissue resident alveolar macrophages, which are biased towards an alternatively-activated, M2-like phenotype, are more permissive to bacterial growth than monocyte-derived, inflammatory, M1-like interstitial macrophages. The differential growth of the bacterium in these different phagocyte populations appears linked to host cell metabolism.
Introduction.
The foundations of our understanding of intracellular parasitism by a range of eukaryote and prokaryote pathogens has been laid using tissue culture infection models. These models, using defined cell lines or expanded primary cell cultures, have been invaluable in the generation of the knowledge base on which the field currently relies. However, the models artificially compress the heterogeneity that exists for all these pathogens in their natural in vivo infection cycle. It is the heterogeneity within the pathogen population that enhances a pathogen’s capacity to adapt and survive under the differing immune pressures and tissue environments within its host (1–3).
The past few years has seen the development of a new generation of tools that will enable us to better understand the functional consequences of heterogeneity both in the pathogen population, and in the subsets of host cells present in vivo (4–6). Mycobacterium tuberculosis (Mtb) is a human pathogen and is the largest single cause of death by a single infectious agent. There are no effective vaccines against infection and no biomarkers for protective immunity (7–10). While there are drugs that are effective against Mtb, treatment requires a cocktail of 3–4 drugs taken continuously for 8–9 months. Such drug regimens are a serious strain on the resources of the healthcare systems in many resource-challenged nations, and the emergence of drug resistant strains occurs with disturbing frequency in many countries. Understanding the consequences of bacterial heterogeneity in vivo with respect to both drug action and immune containment remains a serious challenge to the field.
The immune environment at site of infection.
While not an obligate intracellular pathogen, Mtb does spend the greatest part of its infection cycle within host phagocytes and the granuloma, the tissue response to Mtb infection, is an extremely macrophage-rich structure (11, 12). Recent data indicate that, following inhalation of infectious Mtb, the bacterium is phagocytosed by alveolar macrophages (AMs) patrolling the airway surface (13). Uptake of Mtb activates an inflammatory response through the stimulatory capacity of the multiple TLR ligands on the bacterial cell wall. The infected AM invades the subtending tissue of the lung and the pro-inflammatory response amplifies. This response leads to the generation of chemokines, such as CCL2, that are the primary drivers of the recruitment of interstitial macrophages (IMs) derived for peripheral blood monocytes in the circulation (14–17). This proinflammatory response persists until the development of an acquired immune response, which in the murine model system, is delayed until 3–4 weeks post-infection because it is dependent on dendritic cells (DCs) carrying Mtb antigen to draining lymph nodes to prime the initial T-cell response to infection (18, 19).
Upon acquisition of a specific immune response against Mtb the replication of the bacterium is restricted and the infection transitions into a containment state with relatively static bacterial burden, Figure 1A. In non-human primates (NHP) and, by inference in humans, the infection is paucibacillary, whereas in mice there is a much greater bacterial burden. This is one of the features of the murine infection that raises concerns regarding its usefulness as a model for human TB. During this phase of containment and cellular consolidation new macrophage phenotypes such as epithelioid macrophages, multi-nucleated giant cells and foamy macrophages appear within the granuloma (20). In NHPs and humans the granuloma is a highly stratified structure with distinct transcriptional signatures associated with the different regions, Figure 1B. The central, caseous region of the granuloma has a pro-inflammatory signature, while the region surrounding the caseum shows marked enrichment for transcripts associated with anti-inflammatory programs (21, 22). Intriguingly, each granuloma functions like an independent entity and, while the systemic immune response appears unchanged, some granulomas may progress to active disease whilst others continue to control the infection, or even progress to a sterile state (23). The factors that determine the localized progression to active disease have remained elusive (24).
This phenomenon reflects one of our greatest obstacles to combating this disease. There are no reliable biomarkers for protective immunity and therefore no surrogates to inform vaccine development programs (7–9). Increasingly sensitive indicators of early disease progression have been reported (25), but these indicators require initiation of the tissue damage that accompanies actual disease so they are not useful indicators of protective immune status. Mycobacterial Growth Inhibition Assays (MGIA) are the most utilized peripheral indicator of protective immunity (26). The data look compelling because they show a functional readout linked to bacterial survival. However, recent comprehensive evaluation of extensive datasets on the application of MGIA on different human populations indicate that, while indicative of trained innate immunity, they do not correlate with the protected state of the individual (27).
Life or death in the Phagocyte.
M. tuberculosis is internalized by classic phagocytosis. Inert particles phagocytosed by macrophages are delivered to the acidic, hydrolytic environment of the phago-lysosome, but M. tuberculosis has evolved strategies to subvert the process of phagosome maturation (28). The compartment in which M. tuberculosis resides is slightly acidified (pH 6.4), remains interactive with the endosomal network, and shows limited acquisition of lysosomal hydrolases. Classic activation of the macrophage with interferon-gamma (IFN-γ) prior to infection enables the macrophage to overcome this process and deliver the bacterium to an acidic lysosome (29, 30). The killing of M. tuberculosis by activated macrophages is dependent on multiple factors, most significantly, the production of nitric oxide (NO), the low pH of the lysosome, and the delivery of antimicrobial peptides through the process of autophagy (31–33).
Several publications document the ability of M. tuberculosis to escape the phagosome and access the cytosol of its host cell (34–37). Escape from the phagosome appears to precipitate the necrotic death of the infected macrophage, and a marked growth spurt in the intracellular bacterial population (38, 39). This transient event that may have significance with respect to the pathology observed in late-stage disease, but may be of less significance to long-term survival of the pathogen in its host. Data indicate that, temporally and spatially, the intravacuolar population of M. tuberculosis likely represents the more significant target for therapeutics (40).
What are the underlying mechanisms of immune control and disease progression?
Our understanding of immune control of tuberculosis is shaped heavily by failed immunity in the form of knockout mouse studies, or catastrophic human genetic lesions (41, 42). IFN-γ is known to be important because mice deficient in IFN-γ fail to control Mtb infection and humans with genetic defects in their IFN-γ receptor are exquisitely susceptible to TB and to BCG’osis. IFN-γ Release Assays (IGRA) have also been used, unsuccessfully, as indicators of a protective immune response or treatment efficacy (43). However, our current knowledge indicates that while a Th1-biased immune response and the production of IFN-γ is required for an effective immune response to Mtb it is not sufficient to protect against either infection, or disease progression. Moreover, the assumption that disease progression is the consequence of failure in Th1-dependent immune control, while widely held, is actually unsubstantiated.
A recent study used fluorescent Mtb fitness reporter strains to identify those host phagocytes that best controlled Mtb growth, and those phagocytes that were permissive (44). The strains all expressed mCherry constitutively and expressed GFP either as a fusion protein with the single strand binding protein (SSB) as a readout for replication, or conditional expression of GFP under regulation of the NO-responsive promoter for hspX(4–6), shown in Figure 2. Studies in vaccinated and naïve mice demonstrated that expression of hspX’::GFP correlated with the development of a Th1 immune response and the expression of iNOS in the host tissue, and that fluorescent SSB-GFP foci were less numerous in the face of a Th1 immune response (5). These data were generated on tissue sections from the murine granulomas. The phenotype of the bacterium at individual cell level was determined on cell suspensions from infected tissue (44). At 2 weeks post-infection the bacteria were present predominantly in neutrophils, AMs and IMs. Upon characterization of the reporter Mtb strains it was found that the levels of stress induction (hspX’:: GFP) were higher in Mtb in IMs and neutrophils, than it was in those bacilli in AMs. Conversely, the SSB-GFP puncti were more frequent in Mtb in AMs and neutrophils than they were in Mtb in IMs. These data suggested that Mtb in AMs experienced less stress and replicated more actively than those in IMs. This result was corroborated with Mtb expressing a clock plasmid, pBP10, which is lost from the bacteria at a fixed rate linked to replication (45, 46).
Clodronate liposome-mediated depletion of the macrophage subsets was conducted to demonstrate the functional significance of the IM and AM host cell populations. Delivery of clodronate liposomes to the lung airways depleted the AM population and intravenous inoculation of clodronate liposomes depleted the blood monocytes and therefore the IM population. In the mice with depleted AM the bacterial burden was reduced by approximately one log, while in the mice with depleted IMs the bacterial burden was increased by a log, Figure 3. These data demonstrate that by altering the relative proportion of IMs and AMs available to act as host phagocytes one can impact the bacterial load in the mice both positively or negatively, an observation consistent with previous macrophage depletion studies (14, 16, 17).
IMs and AMs adopt markedly differing metabolic states in response to Mtb infection.
Analysis of the transcriptional profiles of both Mtb-infected and uninfected IMs and AMs showed that all four phagocyte populations had their own discrete signature (44). Pathway analysis of the Mtb-infected AMs and IMs indicated that infected AMs were enriched for transcripts associated with fatty acid metabolism and cholesterol homeostasis. In contrast, infected IMs were up-regulated in transcripts linked to inflammatory responses, glycolysis, IFN-γsignaling and hypoxia. Treatment of infected mice with the non-hydrolyzable glucose analog 2-deoxyglucose (2-DG) led to a decrease in IM number without impacting the AM population. The reduction in IM number was accompanied by an increase in bacterial burden, providing independent demonstration that the reduction in the relative proportion of IM/AMs drives an expansion in the bacterial burden.
A functional link between host cell metabolism and bacterial growth was demonstrated through the manipulation of Mtb-infected bone marrow-derived macrophages (BMDMs) with the metabolic inhibitors 2-DG and the fatty acid oxidation inhibitor Etomoxir (ETO) in vitro. Inhibition of glycolysis in the infected BMDM enhanced bacterial growth, while inhibition of fatty acid oxidation with ETO led to a reduction in bacterial growth. Neither compound had any impact on bacterial growth in rich Middlebrook 7H9 bacterial broth.
What is the basis of the difference between AM and IM?
Until very recently it was thought that all macrophages in the body were differentiated from peripheral blood monocytes derived from hematopoietic precursors in the bone marrow. This is now known not to be the case and most tissue resident macrophages, including alveolar macrophages, derive from fetal yolk sac and fetal liver stem cells during embryogenesis (47, 48). These tissue resident cells are self-maintaining and capable of replication, albeit at a slow rate during homeostasis. Interestingly, recent reports suggest that Mtb-infection arrests cell cycle in infected cells while increasing bystander macrophage replication within the infected tissue (44, 49). A similar state of monocytosis has been observed in human tuberculosis indicating that this response is not restricted to the murine infection model (50, 51). The induction of replication within the macrophage populations in the infected lung provides another route for the selective expansion of permissive AM population.
The larger question emerging from these studies is how the IM and AMs lineages, that experience the same immune milieu generated by Mtb infection, adopt such divergent metabolic states. IMs and AMs are ontologically-distinct macrophage lineages suggesting that ontogeny is the dominant determinant controlling their response to infection. This interpretation is supported by recent data from an acute lung injury model where IMs and AMs experiencing LPS in the lung responded divergently despite experiencing the same insult (52). The accepted tissue culture model for macrophage polarization invokes the adoption of an M1 (inflammatory and anti-microbial) state in response to IFN-γ, and the acquisition of an M2 (anti-inflammatory and tissue repair) state following exposure to IL-4 and IL-13 (53–55). While these definitions provide a useful sense of context, multiple labs report that in vivo, in both humans and mice, different macrophage populations co-express numerous proteins or transcripts that, in vitro are thought to associate exclusively with either M1 or M2 activation states (56, 57). Extensive analysis and modeling of macrophage subsets in NHP tuberculosis infection has detailed different populations of macrophages that express M1- (eNOS and iNOS) or M2- (Arg1 and Arg2) associated markers (58). In a subsequent model they suggest that the relative ratio of M1/M2 macrophage subsets is an accurate predictor of whether any individual granuloma is likely to progress to active disease (59). The model is consistent with data indicating that ontogenically-distinct macrophage populations, the AMs and IMs, are actually pre-programmed to respond divergently when experiencing the same immunological milieu during Mtb infection. Analysis of PBMC-derived macrophages and tissue resident macrophages under homeostatic conditions suggests that the bias towards M1-like and M2-like phenotypes in these different macrophage lineages exists prior to any insult or infection (60, 61).
Bacterial metabolism in the host environment.
The advances in our understanding of host cell metabolism and bacterial control now connects with our appreciation of bacterial metabolism within the host cell environment. Mtb’s preference for lipids and fatty acids as carbon source has been discussed since the 1950’s but the central significance of this metabolic dependence to the virulence and pathogenesis of Mtb has only been demonstrated experimentally recently. In 2000 McKinney and colleagues reported that mutants of Mtb deficient in expression of isocitrate lyase (icl1) could not sustain an infection in the face of immune pressure (62). Isocitrate lyase of Mtb is a bifunctional enzyme whose more significant activity is that of a methyl isocitrate lyase that is required for the Methylcitrate Cycle, which is the primary route for detoxification of the proponyl-CoA that accumulates upon degradation of cholesterol (63–66).
Mtb has specific transport systems dedicated to the acquisition of fatty acids and cholesterol. The Mce family of lipid transporters is conserved across the bacterial kingdom (67), and is present in Mtb as 4 distinct multi-genic transporter complexes (68). Mce1 and Mce4 are the preferred uptake transporters for fatty acids and for cholesterol respectively (69). The two transporters share some of their subunit proteins, which stabilize the transporter complexes, and most notably, all Mce transporters use a common motor, the ATPase MceG (69). The linking of fatty acid and cholesterol acquisition is not surprising given the requirement for the balanced production of downstream intermediates to feed the TCA cycle and provide building blocks for the synthesis of complex cell wall lipids (63, 66).
The significance of cholesterol to Mtb growth was also demonstrated by a large empirical screen to identify compounds active against intracellular Mtb (70). The screen identified several inhibitors that blocked specific steps in bacterial cholesterol degradation, or its regulation, Figure 5. In addition, transcriptional profiling from a panel of 15 clinical strains of Mtb that represented the global genetic diversity of the Mycobacterium tuberculosis complex confirmed that genes involved in the processing of cholesterol and fatty acids were up-regulated during intracellular growth as part of common core transcriptome shared across all isolates (71).
The coupled metabolism of host and pathogen.
While it is clear that the metabolism of Mtb is shifted towards heavy dependence on fatty acids and cholesterol, and that the predisposition of the AM population towards fatty acid oxidation appears to provide Mtb with a permissive host cell population, the modulation of host metabolism extends beyond the host cell to the surrounding tissue.
Figure 1B illustrates the caseous center of the human TB granuloma. TLC and mass spectrometry analysis of the lipid species in the human granuloma demonstrated that the major lipid species were triacylglycerols (TAG), cholesterol and cholesterol ester (CE) (21). The presence of abundant CE in in the caseum is strong evidence that these lipids came from lipid droplets present in the foamy macrophages that typically surround the caseous center of the granuloma (72, 73). When cells accumulate cholesterol, they usually esterify the sterol prior to transport from the ER and incorporation into the lipid droplet. This esterification is proposed to reduce the toxicity of the cholesterol. Mtb-infection in culture induces a foamy macrophage phenotype in the infected cell, and in uninfected bystander macrophages in the same culture. The mycobacterial cell wall lipid trehalose dimycolate (TDM) has been shown to induce this behavior (72). TDM is recognized by the scavenger receptor MARCO and signals through both TLR2 and Mincle (74, 75). It is thought that the prolonged, chronic activation of the proinflammatory pathways in macrophages drives this transformation into foamy cells, Figure 6, similar to the cascade invoked in atherosclerotic plaques.
Concluding Remarks.
It is interesting to see how evolution appears to have driven Mtb to exploit the nutrient sources that it has the capacity to enhance at site of infection, thus maximizing its chance of success. But the odds are not entirely in favor of Mtb. Of those individuals that acquire an Mtb infection, during the course of their lifetime only 5–10 % of immunecompetent individuals will progress to develop active disease. These look pretty good odds for the human species. However, the problem comes with the extraordinary efficiency of transmission that enables a single individual with active TB to infect a large number of people. Recent estimates had indicated that approximately 25% of the world’s population is sub-clinically infected with Mtb (76). In areas of high HIV endemnicity, such as Sub-Saharan Africa, this constitutes a major challenge to human health. Not only is Mtb that largest single cause of death by an infectious agent, it is also the single greatest cause of death in individuals living with HIV. The challenges remain, but our increased knowledge of the physiology and metabolism of intracellular Mtb, and its interplay with the different host macrophage populations, will likely provide new avenues to combat this pathogen.
Acknowledgements.
DGR, EVN and LH are supported by awards from the National Institutes of Health (AI 118582 and AI134183), and by funds from the Bill and Melinda Gates Foundation (OPP1108452 and OPP1156451).
References
- 1.Aldridge BB, Fernandez-Suarez M, Heller D, Ambravaneswaran V, Irimia D, Toner M, Fortune SM. 2012. Asymmetry and aging of mycobacterial cells lead to variable growth and antibiotic susceptibility. Science 335:100–104. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Manina G, Dhar N, McKinney JD. 2015. Stress and host immunity amplify Mycobacterium tuberculosis phenotypic heterogeneity and induce nongrowing metabolically active forms. Cell Host Microbe 17:32–46. [DOI] [PubMed] [Google Scholar]
- 3.Rego EH, Audette RE, Rubin EJ. 2017. Deletion of a mycobacterial divisome factor collapses single-cell phenotypic heterogeneity. Nature 546:153–157. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Abramovitch RB, Rohde KH, Hsu FF, Russell DG. 2011. aprABC: a Mycobacterium tuberculosis complex-specific locus that modulates pH-driven adaptation to the macrophage phagosome. Mol Microbiol 80:678–694. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Sukumar N, Tan S, Aldridge BB, Russell DG. 2014. Exploitation of Mycobacterium tuberculosis reporter strains to probe the impact of vaccination at sites of infection. PLoS Pathog 10:e1004394. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Tan S, Sukumar N, Abramovitch RB, Parish T, Russell DG. 2013. Mycobacterium tuberculosis responds to chloride and pH as synergistic cues to the immune status of its host cell. PLoS Pathog 9:e1003282. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Bhatt K, Verma S, Ellner JJ, Salgame P. 2015. Quest for correlates of protection against tuberculosis. Clin Vaccine Immunol 22:258–266. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Cadena AM, Flynn JL, Fortune SM. 2016. The Importance of First Impressions: Early Events in Mycobacterium tuberculosis Infection Influence Outcome. MBio 7:e00342–00316. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Goletti D, Petruccioli E, Joosten SA, Ottenhoff TH. 2016. Tuberculosis Biomarkers: From Diagnosis to Protection. Infect Dis Rep 8:6568. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Huang L, Russell DG. 2017. Protective immunity against tuberculosis: what does it look like and how do we find it? Curr Opin Immunol 48:44–50. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Flynn JL, Gideon HP, Mattila JT, Lin PL. 2015. Immunology studies in non-human primate models of tuberculosis. Immunol Rev 264:60–73. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Russell DG. 2007. Who puts the tubercle in tuberculosis? Nat Rev Microbiol 5:39–47. [DOI] [PubMed] [Google Scholar]
- 13.Cohen SB, Gern BH, Delahaye JL, Adams KN, Plumlee CR, Winkler JK, Sherman DR, Gerner MY, Urdahl KB. 2018. Alveolar Macrophages Provide an Early Mycobacterium tuberculosis Niche and Initiate Dissemination. Cell Host Microbe doi: 10.1016/j.chom.2018.08.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Antonelli LR, Gigliotti Rothfuchs A, Goncalves R, Roffe E, Cheever AW, Bafica A, Salazar AM, Feng CG, Sher A. 2010. Intranasal Poly-IC treatment exacerbates tuberculosis in mice through the pulmonary recruitment of a pathogen-permissive monocyte/macrophage population. J Clin Invest 120:1674–1682. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Kipnis A, Basaraba RJ, Orme IM, Cooper AM. 2003. Role of chemokine ligand 2 in the protective response to early murine pulmonary tuberculosis. Immunology 109:547–551. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Leemans JC, Juffermans NP, Florquin S, van Rooijen N, Vervoordeldonk MJ, Verbon A, van Deventer SJ, van der Poll T. 2001. Depletion of alveolar macrophages exerts protective effects in pulmonary tuberculosis in mice. J Immunol 166:4604–4611. [DOI] [PubMed] [Google Scholar]
- 17.Samstein M, Schreiber HA, Leiner IM, Susac B, Glickman MS, Pamer EG. 2013. Essential yet limited role for CCR2(+) inflammatory monocytes during Mycobacterium tuberculosis-specific T cell priming. Elife 2:e01086. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Wolf AJ, Desvignes L, Linas B, Banaiee N, Tamura T, Takatsu K, Ernst JD. 2008. Initiation of the adaptive immune response to Mycobacterium tuberculosis depends on antigen production in the local lymph node, not the lungs. J Exp Med 205:105–115. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Wolf AJ, Linas B, Trevejo-Nunez GJ, Kincaid E, Tamura T, Takatsu K, Ernst JD. 2007. Mycobacterium tuberculosis infects dendritic cells with high frequency and impairs their function in vivo. J Immunol 179:2509–2519. [DOI] [PubMed] [Google Scholar]
- 20.Flynn JL, Chan J, Lin PL. 2011. Macrophages and control of granulomatous inflammation in tuberculosis. Mucosal Immunol 4:271–278. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Kim MJ, Wainwright HC, Locketz M, Bekker LG, Walther GB, Dittrich C, Visser A, Wang W, Hsu FF, Wiehart U, Tsenova L, Kaplan G, Russell DG. 2010. Caseation of human tuberculosis granulomas correlates with elevated host lipid metabolism. EMBO Mol Med 2:258–274. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Marakalala MJ, Raju RM, Sharma K, Zhang YJ, Eugenin EA, Prideaux B, Daudelin IB, Chen PY, Booty MG, Kim JH, Eum SY, Via LE, Behar SM, Barry CE 3rd, Mann M, Dartois V, Rubin EJ. 2016. Inflammatory signaling in human tuberculosis granulomas is spatially organized. Nat Med 22:531–538. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Lin PL, Ford CB, Coleman MT, Myers AJ, Gawande R, Ioerger T, Sacchettini J, Fortune SM, Flynn JL. 2014. Sterilization of granulomas is common in active and latent tuberculosis despite within-host variability in bacterial killing. Nat Med 20:75–79. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Cadena AM, Fortune SM, Flynn JL. 2017. Heterogeneity in tuberculosis. Nat Rev Immunol 17:691–702. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Petruccioli E, Scriba TJ, Petrone L, Hatherill M, Cirillo DM, Joosten SA, Ottenhoff TH, Denkinger CM, Goletti D. 2016. Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosis. Eur Respir J 48:1751–1763. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Tanner R, O’Shea MK, Fletcher HA, McShane H. 2016. In vitro mycobacterial growth inhibition assays: A tool for the assessment of protective immunity and evaluation of tuberculosis vaccine efficacy. Vaccine 34:4656–4665. [DOI] [PubMed] [Google Scholar]
- 27.Joosten SA, Meijgaarden KEV, Arend SM, Prins C, Oftung F, Korsvold GE, Kik SV, Arts RJ, Crevel RV, Netea MG, Ottenhoff TH. 2018. Mycobacterial growth inhibition is associated with trained innate immunity. J Clin Invest doi: 10.1172/JCI97508. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.VanderVen BC, Huang L, Rohde KH, Russell DG. 2016. The Minimal Unit of Infection: Mycobacterium tuberculosis in the Macrophage. Microbiol Spectr 4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Schaible UE, Sturgill-Koszycki S, Schlesinger PH, Russell DG. 1998. Cytokine activation leads to acidification and increases maturation of Mycobacterium avium-containing phagosomes in murine macrophages. J Immunol 160:1290–1296. [PubMed] [Google Scholar]
- 30.Via LE, Fratti RA, McFalone M, Pagan-Ramos E, Deretic D, Deretic V. 1998. Effects of cytokines on mycobacterial phagosome maturation. J Cell Sci 111 ( Pt 7):897–905. [DOI] [PubMed] [Google Scholar]
- 31.Alonso S, Pethe K, Russell DG, Purdy GE. 2007. Lysosomal killing of Mycobacterium mediated by ubiquitin-derived peptides is enhanced by autophagy. Proc Natl Acad Sci U S A 104:6031–6036. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Gutierrez MG, Master SS, Singh SB, Taylor GA, Colombo MI, Deretic V. 2004. Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. Cell 119:753–766. [DOI] [PubMed] [Google Scholar]
- 33.MacMicking JD, North RJ, LaCourse R, Mudgett JS, Shah SK, Nathan CF. 1997. Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc Natl Acad Sci U S A 94:5243–5248. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.McDonough KA, Kress Y, Bloom BR. 1993. Pathogenesis of tuberculosis: interaction of Mycobacterium tuberculosis with macrophages. Infect Immun 61:2763–2773. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Myrvik QN, Leake ES, Wright MJ. 1984. Disruption of phagosomal membranes of normal alveolar macrophages by the H37Rv strain of Mycobacterium tuberculosis. A correlate of virulence. Am Rev Respir Dis 129:322–328. [PubMed] [Google Scholar]
- 36.Simeone R, Bobard A, Lippmann J, Bitter W, Majlessi L, Brosch R, Enninga J. 2012. Phagosomal rupture by Mycobacterium tuberculosis results in toxicity and host cell death. PLoS Pathog 8:e1002507. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.van der Wel N, Hava D, Houben D, Fluitsma D, van Zon M, Pierson J, Brenner M, Peters PJ. 2007. M. tuberculosis and M. leprae translocate from the phagolysosome to the cytosol in myeloid cells. Cell 129:1287–1298. [DOI] [PubMed] [Google Scholar]
- 38.Lerner TR, Borel S, Greenwood DJ, Repnik U, Russell MR, Herbst S, Jones ML, Collinson LM, Griffiths G, Gutierrez MG. 2017. Mycobacterium tuberculosis replicates within necrotic human macrophages. J Cell Biol 216:583–594. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Mahamed D, Boulle M, Ganga Y, Mc Arthur C, Skroch S, Oom L, Catinas O, Pillay K, Naicker M, Rampersad S, Mathonsi C, Hunter J, Wong EB, Suleman M, Sreejit G, Pym AS, Lustig G, Sigal A. 2017. Intracellular growth of Mycobacterium tuberculosis after macrophage cell death leads to serial killing of host cells. Elife 6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Russell DG. 2016. The ins and outs of the Mycobacterium tuberculosis-containing vacuole. Cell Microbiol doi: 10.1111/cmi.12623. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Boisson-Dupuis S, Bustamante J, El-Baghdadi J, Camcioglu Y, Parvaneh N, El Azbaoui S, Agader A, Hassani A, El Hafidi N, Mrani NA, Jouhadi Z, Ailal F, Najib J, Reisli I, Zamani A, Yosunkaya S, Gulle-Girit S, Yildiran A, Cipe FE, Torun SH, Metin A, Atikan BY, Hatipoglu N, Aydogmus C, Kilic SS, Dogu F, Karaca N, Aksu G, Kutukculer N, Keser-Emiroglu M, Somer A, Tanir G, Aytekin C, Adimi P, Mahdaviani SA, Mamishi S, Bousfiha A, Sanal O, Mansouri D, Casanova JL, Abel L. 2015. Inherited and acquired immunodeficiencies underlying tuberculosis in childhood. Immunol Rev 264:103–120. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.North RJ, Jung YJ. 2004. Immunity to tuberculosis. Annu Rev Immunol 22:599–623. [DOI] [PubMed] [Google Scholar]
- 43.Clifford V, He Y, Zufferey C, Connell T, Curtis N. 2015. Interferon gamma release assays for monitoring the response to treatment for tuberculosis: A systematic review. Tuberculosis (Edinb) 95:639–650. [DOI] [PubMed] [Google Scholar]
- 44.Huang L, Nazarova EV, Tan S, Liu Y, Russell DG. 2018. Growth of Mycobacterium tuberculosis in vivo segregates with host macrophage metabolism and ontogeny. J Exp Med doi: 10.1084/jem.20172020. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Gill WP, Harik NS, Whiddon MR, Liao RP, Mittler JE, Sherman DR. 2009. A replication clock for Mycobacterium tuberculosis. Nat Med 15:211–214. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Rohde KH, Veiga DF, Caldwell S, Balazsi G, Russell DG. 2012. Linking the transcriptional profiles and the physiological states of Mycobacterium tuberculosis during an extended intracellular infection. PLoS Pathog 8:e1002769. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Guilliams M, De Kleer I, Henri S, Post S, Vanhoutte L, De Prijck S, Deswarte K, Malissen B, Hammad H, Lambrecht BN. 2013. Alveolar macrophages develop from fetal monocytes that differentiate into long-lived cells in the first week of life via GM-CSF. J Exp Med 210:1977–1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Jakubzick CV, Randolph GJ, Henson PM. 2017. Monocyte differentiation and antigen-presenting functions. Nat Rev Immunol 17:349–362. [DOI] [PubMed] [Google Scholar]
- 49.Cumming BM, Rahman MA, Lamprecht DA, Rohde KH, Saini V, Adamson JH, Russell DG, Steyn AJC. 2017. Mycobacterium tuberculosis arrests host cycle at the G1/S transition to establish long term infection. PLoS Pathog 13:e1006389. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.La Manna MP, Orlando V, Dieli F, Di Carlo P, Cascio A, Cuzzi G, Palmieri F, Goletti D, Caccamo N. 2017. Quantitative and qualitative profiles of circulating monocytes may help identifying tuberculosis infection and disease stages. PLoS One 12:e0171358. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Wang J, Yin Y, Wang X, Pei H, Kuai S, Gu L, Xing H, Zhang Y, Huang Q, Guan B. 2015. Ratio of monocytes to lymphocytes in peripheral blood in patients diagnosed with active tuberculosis. Braz J Infect Dis 19:125–131. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Mould KJ, Barthel L, Mohning MP, Thomas SM, McCubbrey AL, Danhorn T, Leach SM, Fingerlin TE, O’Connor BP, Reisz JA, D’Alessandro A, Bratton DL, Jakubzick CV, Janssen WJ. 2017. Cell Origin Dictates Programming of Resident versus Recruited Macrophages during Acute Lung Injury. Am J Respir Cell Mol Biol 57:294–306. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Bosca L, Gonzalez-Ramos S, Prieto P, Fernandez-Velasco M, Mojena M, Martin-Sanz P, Alemany S. 2015. Metabolic signatures linked to macrophage polarization: from glucose metabolism to oxidative phosphorylation. Biochem Soc Trans 43:740–744. [DOI] [PubMed] [Google Scholar]
- 54.Verdeguer F, Aouadi M. 2017. Macrophage heterogeneity and energy metabolism. Exp Cell Res 360:35–40. [DOI] [PubMed] [Google Scholar]
- 55.Zhu L, Zhao Q, Yang T, Ding W, Zhao Y. 2015. Cellular metabolism and macrophage functional polarization. Int Rev Immunol 34:82–100. [DOI] [PubMed] [Google Scholar]
- 56.Ruckerl D, Campbell SM, Duncan S, Sutherland TE, Jenkins SJ, Hewitson JP, Barr TA, Jackson-Jones LH, Maizels RM, Allen JE. 2017. Macrophage origin limits functional plasticity in helminth-bacterial co-infection. PLoS Pathog 13:e1006233. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Zhu Y, Herndon JM, Sojka DK, Kim KW, Knolhoff BL, Zuo C, Cullinan DR, Luo J, Bearden AR, Lavine KJ, Yokoyama WM, Hawkins WG, Fields RC, Randolph GJ, DeNardo DG. 2017. Tissue-Resident Macrophages in Pancreatic Ductal Adenocarcinoma Originate from Embryonic Hematopoiesis and Promote Tumor Progression. Immunity 47:323–338 e326. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Mattila JT, Ojo OO, Kepka-Lenhart D, Marino S, Kim JH, Eum SY, Via LE, Barry CE 3rd, Klein E, Kirschner DE, Morris SM Jr., Lin PL, Flynn JL. 2013. Microenvironments in tuberculous granulomas are delineated by distinct populations of macrophage subsets and expression of nitric oxide synthase and arginase isoforms. J Immunol 191:773–784. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Marino S, Cilfone NA, Mattila JT, Linderman JJ, Flynn JL, Kirschner DE. 2015. Macrophage polarization drives granuloma outcome during Mycobacterium tuberculosis infection. Infect Immun 83:324–338. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Gibbings SL, Goyal R, Desch AN, Leach SM, Prabagar M, Atif SM, Bratton DL, Janssen W, Jakubzick CV. 2015. Transcriptome analysis highlights the conserved difference between embryonic and postnatal-derived alveolar macrophages. Blood 126:1357–1366. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Gibbings SL, Thomas SM, Atif SM, McCubbrey AL, Desch AN, Danhorn T, Leach SM, Bratton DL, Henson PM, Janssen WJ, Jakubzick CV. 2017. Three Unique Interstitial Macrophages in the Murine Lung at Steady State. Am J Respir Cell Mol Biol doi: 10.1165/rcmb.2016-0361OC. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.McKinney JD, Honer zu Bentrup K, Munoz-Elias EJ, Miczak A, Chen B, Chan WT, Swenson D, Sacchettini JC, Jacobs WR Jr., Russell DG. 2000. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature 406:735–738. [DOI] [PubMed] [Google Scholar]
- 63.Lee W, VanderVen BC, Fahey RJ, Russell DG. 2013. Intracellular Mycobacterium tuberculosis exploits host-derived fatty acids to limit metabolic stress. J Biol Chem 288:6788–6800. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64.Munoz-Elias EJ, McKinney JD. 2005. Mycobacterium tuberculosis isocitrate lyases 1 and 2 are jointly required for in vivo growth and virulence. Nat Med 11:638–644. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65.Munoz-Elias EJ, Upton AM, Cherian J, McKinney JD. 2006. Role of the methylcitrate cycle in Mycobacterium tuberculosis metabolism, intracellular growth, and virulence. Mol Microbiol 60:1109–1122. [DOI] [PubMed] [Google Scholar]
- 66.Savvi S, Warner DF, Kana BD, McKinney JD, Mizrahi V, Dawes SS. 2008. Functional characterization of a vitamin B12-dependent methylmalonyl pathway in Mycobacterium tuberculosis: implications for propionate metabolism during growth on fatty acids. J Bacteriol 190:3886–3895. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.Ekiert DC, Bhabha G, Isom GL, Greenan G, Ovchinnikov S, Henderson IR, Cox JS, Vale RD. 2017. Architectures of Lipid Transport Systems for the Bacterial Outer Membrane. Cell 169:273–285 e217. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68.Zhang F, Xie JP. 2011. Mammalian cell entry gene family of Mycobacterium tuberculosis. Mol Cell Biochem 352:1–10. [DOI] [PubMed] [Google Scholar]
- 69.Nazarova EV, Montague CR, La T, Wilburn KM, Sukumar N, Lee W, Caldwell S, Russell DG, VanderVen BC. 2017. Rv3723/LucA coordinates fatty acid and cholesterol uptake in Mycobacterium tuberculosis. Elife 6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 70.VanderVen BC, Fahey RJ, Lee W, Liu Y, Abramovitch RB, Memmott C, Crowe AM, Eltis LD, Perola E, Deininger DD, Wang T, Locher CP, Russell DG. 2015. Novel inhibitors of cholesterol degradation in Mycobacterium tuberculosis reveal how the bacterium’s metabolism is constrained by the intracellular environment. PLoS Pathog 11:e1004679. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 71.Homolka S, Niemann S, Russell DG, Rohde KH. 2010. Functional genetic diversity among Mycobacterium tuberculosis complex clinical isolates: delineation of conserved core and lineage-specific transcriptomes during intracellular survival. PLoS Pathog 6:e1000988. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 72.Peyron P, Vaubourgeix J, Poquet Y, Levillain F, Botanch C, Bardou F, Daffe M, Emile JF, Marchou B, Cardona PJ, de Chastellier C, Altare F. 2008. Foamy macrophages from tuberculous patients’ granulomas constitute a nutrient-rich reservoir for M. tuberculosis persistence. PLoS Pathog 4:e1000204. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 73.Russell DG, Cardona PJ, Kim MJ, Allain S, Altare F. 2009. Foamy macrophages and the progression of the human tuberculosis granuloma. Nat Immunol 10:943–948. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 74.Bowdish DM, Sakamoto K, Kim MJ, Kroos M, Mukhopadhyay S, Leifer CA, Tryggvason K, Gordon S, Russell DG. 2009. MARCO, TLR2, and CD14 are required for macrophage cytokine responses to mycobacterial trehalose dimycolate and Mycobacterium tuberculosis. PLoS Pathog 5:e1000474. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 75.Ishikawa E, Ishikawa T, Morita YS, Toyonaga K, Yamada H, Takeuchi O, Kinoshita T, Akira S, Yoshikai Y, Yamasaki S. 2009. Direct recognition of the mycobacterial glycolipid, trehalose dimycolate, by C-type lectin Mincle. J Exp Med 206:2879–2888. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 76.Houben RM, Dodd PJ. 2016. The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling. PLoS Med 13:e1002152. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 77.Russell DG, VanderVen BC, Lee W, Abramovitch RB, Kim MJ, Homolka S, Niemann S, Rohde KH. 2010. Mycobacterium tuberculosis wears what it eats. Cell Host Microbe 8:68–76. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 78.Podinovskaia M, Lee W, Caldwell S, Russell DG. 2013. Infection of macrophages with Mycobacterium tuberculosis induces global modifications to phagosomal function. Cell Microbiol 15:843–859. [DOI] [PMC free article] [PubMed] [Google Scholar]